Monoclonal antibodies against TNF-α, IL-17, and IL-23 were found to mediate a strong anti-inflammatory effect that has been already implemented for the treatment of psoriasis patients and proved to be highly efficacious [25, 27–31]. The gene discussed is IL17A; the disease is psoriasis.